Other substances

Fosamprenavir

An HIV protease inhibitor.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

2
 Supporting references
0
 Contradictory references
4
 AI-suggested references
0
 Clinical trials

General information

Fosamprenavir on PubChem

Marketed as

FOSAMPRENAVIR CALCIUM; LEXIVA; TELZIR

 

Structure image - Fosamprenavir

CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)OP(=O)(O)O)S(=O)(=O)C3=CC=C(C=C3)N

Supporting references

Link Tested on Impact factor Notes Publication date
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
in silico Feb/22/2020
MCCS: a novel recognition pattern-based method for fast track discovery of anti-SARS-CoV-2 drugs
3CLpro Small molecule In silico 		in silico 8.99

Predicted to inhibit the SARS-CoV-2 3C-like protease.

 Oct/20/2020

AI-suggested references

Link Publication date
Identification of potential antivirals against SARS-CoV-2 using virtual screening method.
Feb/10/2021
Computational Evaluation of the Inhibition Efficacies of HIV Antivirals on SARS-CoV-2 (COVID-19) Protease and Identification of 3D Pharmacophore and Hit Compounds.
Sep/21/2020
Identification of potential natural inhibitors of the receptor-binding domain of the SARS-CoV-2 spike protein using a computational docking approach
Aug/21/2020
Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19)
Jun/27/2020
Export (.csv)